In vivo, EVs accelerated tumor growth and activated prosurvival (p-AKT, BCL-2), angiogenic (VEGFA, CD31), and epithelial-mesenchymal transition-associated (vimentin) pathways. The gene discussed is VEGFA; the disease is neoplasm.